小细胞支气管癌的化疗：洛莫司汀与阿霉素联合用药与洛莫司汀、阿霉素、长春新碱及丙卡巴肼联合用药的比较
Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine.
作者信息
Vogelzang N J, Trowbridge R C, Frenning D H, Theologides A, Kennedy B J, Kelly D R, Ewing S L, Vosika G J
出版信息
Cancer Treat Rep. 1980 Aug-Sep;64(8-9):997-1000.
Forty consecutive patients with small cell bronchogenic carcinoma were treated. The first 18 patients were treated with CCNU and doxorubicin (Adriamycin) (CA). The next 22 patients were treated with CCNU, doxorubicin, procarbazine, and vincristine (CAPO). Patient characteristics were similar. The partial plus complete response rate was 55% (ten of 18 patients) in the CA group compared to 41% (nine of 22 patients) in the CAPO group. The median survival from treatment was 28 weeks in the CA group compared to 33 weeks in the CAPO group. There were no drug-related deaths among the patients receiving CA compared to two definite and three probably drug-related deaths among the patients receiving CAPO. The addition of procarbazine and vincristine to CA for the treatment of small cell bronchogenic carcinoma resulted in increased toxicity and no survival benefit.
对40例连续性小细胞支气管癌患者进行了治疗。前18例患者接受洛莫司汀和阿霉素（阿霉素）（CA）治疗。接下来的22例患者接受洛莫司汀、阿霉素、丙卡巴肼和长春新碱（CAPO）治疗。患者特征相似。CA组的部分加完全缓解率为55%（18例患者中的10例），而CAPO组为41%（22例患者中的9例）。CA组治疗后的中位生存期为28周，而CAPO组为33周。接受CA治疗的患者中没有与药物相关的死亡，而接受CAPO治疗的患者中有2例明确和3例可能与药物相关的死亡。在CA治疗小细胞支气管癌时添加丙卡巴肼和长春新碱会导致毒性增加且无生存益处。
Zotero 插件